摘要
目的:分析成人重症水痘患者的临床特征,提高对该病的认识。方法:回顾性分析我院重症二科2018年1月至2024年3月收治的18例成人重症水痘患者的临床资料。结果:18例患者中男12例、女6例,平均年龄32.1岁(18~50岁),9例(50.0%)因器官移植、类风湿关节炎等基础疾病长期使用免疫抑制药物。异常实验室结果主要包括血小板计数降低12例(66.7%)、肝酶升高15例(83.3%)、心肌酶升高18例(100%)、N氨基末端脑钠肽升高15例(83.3%)、D-二聚体升高16例(88.9%)、降钙素原升高14例(77.8%)。6例(33.3%)因治疗效果不佳自动出院(3例)或死亡(3例)。15例(83.3%)合并肺部感染,其中11例合并Ⅰ型呼吸衰竭。结论:成人重症水痘患者以男性居多,死亡率较高。免疫抑制个体是成人重症水痘的高发人群。成人重症水痘合并肺部感染患者Ⅰ型呼吸衰竭发生率高。
Objective:To analyze the clinical characteristics of adult patients with severe varicella,and enhance the understanding of this disease.Methods:The clinical data of 18 patients with severe varicella admitted to our hospital from January 2018 to March 2024 were retrospectively analyzed.Results:Of the 18 patients,12 were males and 6 were females.The average age was 32.1 years(ranging from 18 to 50).Nine patients(50.0%)received long-term immunosuppressive drugs due to organ transplantation,rheumatoid arthritis,or other underlying diseases.Multiple laboratory abnormalities included decreased platelet count(12 cases,66.7%),elevated liver enzyme(15 cases,83.3%),elevated myocardial enzyme(18 cases,100%),elevated NT-pro BNP(15 cases,83.3%),elevated D-dimer(16 cases,88.9%),and elevated procalcitonin(14 cases,77.8%).Six patients(33.3%)discontinued treatment due to poor outcomes,of them,3 cases died.There were 15 patients infected with pneumonia,and 11 patients had typeⅠrespiratory failure.Conclusions:Severe varicella is more prevalent in adult males,and has a relatively high mortality rate.Immunocompromised adults are at higher risk for severe varicella infection.TypeⅠrespiratory failure is frequently observed in adults with severe varicella complicated with pulmonary infection.
作者
杜清
陈红
赵玄
冉启惠
邓超
赵本南
DU Qing;CHEN Hong;ZHAO Xuan;RAN Qihui;DENG Chao;ZHAO Bennan(The Second Ward of ICU,Public Health Clinical Center of Chengdu,Chengdu 610061,China;The First Ward of Internal Medicine,Public Health Clinical Center of Chengdu,Chengdu 610061,China)
出处
《中国麻风皮肤病杂志》
2025年第1期43-47,共5页
China Journal of Leprosy and Skin Diseases
基金
2020年四川、重庆联合实施重点研发项目(编号:cstc2020jscx-cylhX0001)
成都市高水平临床重点专科建设项目-传染病学专项。